Recently, 'the Acute Dialysis Quality Initiative (ADQI) workgroup, ' 1 proposed a new classification for acute kidney injury (AKI), 'RIFLE' (Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease), which defines AKI as an increase of serum creatinine of at least 50% from baseline or a decrease of glomerular filtration rate greater than 25% or urine output lower than 0.5 ml/kg/ min for at least 6 h. It also considers three levels of renal dysfunction (risk, injury and failure) and two outcome classes (loss of kidney function and end-stage kidney disease). RIFLE has been used in multiple studies, [2] [3] [4] [5] and it has been shown to be a good tool for the prognostic stratification of the hospitalized patients in general, as well as in the intensive care unit setting. In a previous study, we found that this scoring system predicts mortality in myeloablative autologous and allogeneic hematopoietic cell transplantation (HCT). However, most recently, the Acute Kidney Injury Network (AKIN) 6 has proposed a new classification for AKI ( Table 1 ) that differs from RIFLE as follows. It reduces the need for a baseline creatinine value but does require at least two creatinine values within 48 h. AKI is defined as an abrupt (within 48 h) reduction in kidney function currently defined as an absolute increase in serum creatinine of more than or equal to 0.3 mg per 100 ml (X26.4 mmol/l), a percentage increase in serum creatinine of more than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg/h for more than 6 h). 'Risk' maps to stage 1, but it also considers an increase in serum creatinine of more than or equal to 0.3 mg per 100 ml (X26.4 mmol/l). 'Injury' and 'Failure' map to stages 2 and 3, respectively. Stage 3 also includes patients who need renal replacement therapy irrespective of the stage they are in at the time of renal replacement therapy, and the two outcome classes 'Loss' and 'End-stage kidney disease' have been removed. These modifications were introduced to confer a greater sensitivity and specificity to this classification as compared with RIFLE. We have applied the AKIN classification 7 in patients who received a myeloablative autologous or allogeneic HCT in our Hospital between January 2003 and December 2004, and have found that in-hospital mortality increased as renal function deteriorated and AKI stages independently were associated with worse outcome.
In the present study, we sought to analyze the influence of AKI after myeloablative autologous and allogeneic HCT patients on long-term patients' survival. For this purpose, we evaluated all patients who received a myeloablative autologous or allogeneic HCT in our Hospital between January 2003 and December 2004. Patients were categorized on serum creatinine, and the maximum AKIN within 100 days post transplant was reported. At least two serum creatinine values within 48 h were considered to define AKI stages. Patient follow-up was considered on 31 December 2006. Cumulative survival was determined by the KaplanMeier method, and log-rank test was employed to analyze statistically significant differences between survival curves. Cox regression was used to determine independent predictors of mortality. A two-tailed Po0.05 was considered significant. Statistical analysis was performed using SPSS version 15.0 for Windows. One hundred and forty patients (86 men, mean age: 32.9 ± 14.69 years) were evaluated. Increase in serum creatinine to more than 300% (43-fold) from baseline (or serum creatinine of more than or equal to 4.0 mg per 100 ml (X354 mmol/l) with an acute increase of at least 0.5 mg per 100 ml (44 mmol/l) Less than 0.3 ml/kg/h for 24 h or anuria for 12 h Abbreviation: AKI ¼ acute kidney injury; RRT ¼ renal replacement therapy. AKI is defined as an abrupt (within 48 h) reduction in kidney function currently defined as an absolute increase in serum creatinine of more than or equal to 0.3 mg per 100 ml (X26.4 mmol/l), a percentage increase in serum creatinine of more than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg/h for more than 6 h). 
